The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.a

Respiratory tract infection incl. pneumonia

Publications

Carranza-Enríquez F, Meade-Aguilar JA, Hinojosa-Azaola A

Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort.

Clinical rheumatology 2022 May 04;; — 2022 May 04

Farhat L, Dara J, Duberstein S, De A

Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.

Drug safety - case reports 2018 May 11;5;22 — 2018 May 11 — 22

Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA

Rituximab in severe, treatment-refractory interstitial lung disease.

Respirology (Carlton, Vic.) 2014 Apr;19;353-9 — 2014 Apr — 353-9